The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China

Jianlin Xu,1,* Guozheng Ding,2,* Xueyan Zhang,1 Bo Jin,1 Yuqing Lou,1 Yanwei Zhang,1 Huiming Wang,1 Dan Wu,3 Baohui Han1 1Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Department of Pulmonary, Anqing Municipal Hospi...

Full description

Bibliographic Details
Main Authors: Xu J, Ding G, Zhang X, Jin B, Lou Y, Zhang Y, Wang H, Wu D, Han B
Format: Article
Language:English
Published: Dove Medical Press 2016-10-01
Series:OncoTargets and Therapy
Subjects:
EGFR TKI
wild-type
NSCLC
second-line
Online Access:https://www.dovepress.com/the-egfr-tyrosine-kinase-inhibitors-as-second-line-therapy-for-egfr-wi-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/the-egfr-tyrosine-kinase-inhibitors-as-second-line-therapy-for-egfr-wi-peer-reviewed-article-OTT

Similar Items